708P PD-L1 as a predictor of survival in patients with metastatic urothelial carcinoma (mUC) from the phase III DANUBE trial of durvalumab (D) or durvalumab plus tremelimumab (D+T) versus standard of care chemotherapy (SoC)
Joaquim Bellmunt(Dana-Farber Cancer Institute), Sophie Wildsmith(AstraZeneca (United Kingdom)), Michiel S. van der Heijden(Zorginstituut Nederland), Natasha Angra(AstraZeneca (United States)), Atsushi Mizokami(Kanazawa University), Go Kimura(Nippon Medical School), Alexandra Drakaki(University of California, Los Angeles), Jill Walker(AstraZeneca (United Kingdom)), Matt D. Galsky(University of California, San Francisco), Feng Xiao(Hengyang Normal University), Thomas Powles(Queen Mary University of London), Z. Wang(AstraZeneca (United States)), Pengcheng He(Guangdong General Hospital), Amod Gupta(Post Graduate Institute of Medical Education and Research), F. Jones(AstraZeneca (United Kingdom)), Martin Scott(AstraZeneca (United Kingdom))
Cited by 2
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k